Albion J. Fitzgerald has served as a member of our board of directors since May 2014 and was appointed as Chairman in July 2014.
Mr. Fitzgerald previously served as Chief Executive Officer and Chairman of the Board of Directors of ManageIQ, Inc., a provider of global cloud IT systems management solutions. Mr. Fitzgerald was appointed as a director of ManageIQ in 2007, and served as strategic consultant to the company from 2007 until April 2012, and as Chief Executive and Chairman from April 2012 until ManageIQ, Inc. was acquired by Red Hat, Inc. in December 2012. In 1992 Mr. Fitzgerald co-founded Novadigm, Inc. (NASDAQ: NVDM), an international provider of IT systems management solutions to Fortune 500 companies and government agencies with customers in 26 countries. He served as its Chairman and Chief Technology Officer from 1992 and Chief Executive Officer from 1995 until its acquisition by Hewlett-Packard in 2004.
Prior to Novadigm, Mr. Fitzgerald founded and served as Chief Executive Officer of Telemetrix, Inc., a provider of enterprise IT systems and network management solutions. From 1980 to 1989, Mr. Fitzgerald was a strategic technology consultant to New York University responsible for architecting, building and managing the university’s computer center and campus-wide multi-media network. Mr. Fitzgerald began his technology career at IBM in 1966.
Mr. Fitzgerald’s extensive experience in founding, funding and building emerging-technology companies, the depth of his technology and business expertise, and his relevant experience as a director and officer of a publicly-traded enterprise software company make him a valuable contributor to our board of directors.
Dr. Nir Barzilai co-founded our company in 2007 and has served as a member of our board of directors since our conversion to a Delaware corporation in 2009.
Dr. Barzilai is the Director of the Institute for Aging Research at the Albert Einstein College of Medicine of Yeshiva University, where he also holds the Ingeborg and Ira Leon Rennert Chair of Aging Research, is a professor in the Departments of Medicine and Genetics and a member of the Diabetes research Center. Dr. Barzilai is also Director of the Paul F. Glenn Center for the Biology of Human Aging Research and of the National Institutes of Health’s (NIH) Nathan Shock Centers of Excellence in the Basic Biology of Aging.
Dr. Barzilai has received numerous awards, including the Beeson Fellow for Aging Research, the Ellison Medical Foundation Senior Scholar in Aging Award, the Paul F. Glenn Foundation Award, the NIA Nathan Shock Award, and the 2010 Irving S. Wright Award of Distinction in Aging Research.
Dr. Barzilai’s leadership in gerontology research and his experience overseeing numerous research programs related to diseases of aging and mitochondrial biology makes him an important contributor to our board of directors.
Dr. Pinchas Cohen co-founded our company in 2007 and has served as a member of our board of directors since our conversion to a Delaware corporation in 2009. He served as our President from 2009 until 2013.
Since April 2012, Dr. Cohen has served as Dean of the Davis School of Gerontology at the University of Southern California. He holds the William and Sylvia Kugel Dean’s Chair in Gerontology and acts as Executive Director of the Ethel Percy Andrus Gerontology Center. Dr. Cohen was a member affiliated with the University of California, Los Angeles School of Medicine, where he was a member of the faculty, until 2012. At the UCLA Mattel Children’s Hospital Dr. Cohen served as Director of Endocrine/Diabetes Research and Training (from 1999 until 2012), Chief of Endocrinology and Diabetes (from 2001 until 2012) and as Vice Chair of Research (from 2011 until 2012). Dr. Cohen was also co-director of the UCSD-UCLA Diabetes and Endocrinology Research Center from 2007 until 2012.
Dr. Cohen has received several awards for his work in the field of aging, including a National Institute of Aging EUREKA Award, the National Institutes of Health Director’s Transformative Research Award and the Glenn Award for Research in Biological Mechanisms of Aging. He serves on the boards of several professional journals and societies, including the American Federation for Aging Research and the Growth Hormone Research Society.
Dr. Cohen’s leadership in gerontology research and his experience overseeing numerous research programs related to diseases of aging and mitochondrial biology makes him an important contributor to our board of directors.
Jon L. Stern joined CohBar in August 2012 and has served as Chief Executive Officer from October 2013 through March 2016. Beginning March 2016, Mr. Stern assumed the new role of Chief Operating Officer. He was appointed to our board of directors in May 2014.
From 2009 to 2011 Mr. Stern served as Chief Operating Officer of The Key Worldwide, a provider of college admissions preparation and coaching services for aspiring students and their families in the U.S. and Asia. From 2006 to 2008, Mr. Stern served as Executive Vice President of Integrated China Media, a Guangzhou, China-based provider of digital entertainment content for the Chinese youth market. From 2003 to 2008, Mr. Stern was a partner in Pacific Arts Group, a publisher and collection of Chinese Contemporary Fine Art. Mr. Stern founded Digital Sparx in 1999, a distributor of digital entertainment content to movie-goers and served as President and CEO of that company until 2002.
In 1986 Mr. Stern founded Cine Coasters, Inc., a developer and distributor of sports stadium and movie theatre products and accessories, and served as its Chief Executive Officer until its sale to a division of Liberty Media in 1998. Mr. Stern holds an MBA from the Marshall School of Business at the University of Southern California and a B.S. in Business Administration from The University of California, Berkeley. Mr. Stern is a full-time employee of our company.
Mr. Stern’s substantial experience as an entrepreneur and senior executive of growth stage companies as well as established businesses and his familiarity with the day-to-day operations of our business make him a valuable contributor to our board of directors.
Mr. Goldberg is a Managing Director at BioVentures Investors, a life science focused venture and private equity investment firm that he co-founded in 1997. Prior to founding BioVentures, Mr. Goldberg served as President and Chief Executive Officer of the Massachusetts Biotechnology Research Institute from 1991 to 1997. During his tenure, MBRI raised $20 million in funding and was responsible for the launch of 24 new companies. From 1987 to 1991, Mr. Goldberg was Vice President, Finance and Corporate Development, CFO, and Treasurer at Safer, Inc., a developer and manufacturer of biopesticides and related products. Prior to joining Safer, he served as Manager, Business Development, at Genetics Institute, one of the earliest biotechnology companies. Mr. Goldberg was also Founding President of the Massachusetts Biotechnology Council and served four terms as its President and as a Director from 1985 to 1997. He is currently a member of the Harvard Medical School Neuroscience Advisory Committee and he previously served as a member of the Beth Israel Deaconess Medical Center Research Advisory Committee and of the board of directors.
Mr. Goldberg has served on a number of corporate boards, including Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) where he chaired the compensation committee and also served on the audit committee. Mr. Goldberg has also recently served on the board of directors of Applied Spine, Ardais, BioValve, AngioLink, Verax Biomedical, Cardiosolutions, Claros Diagnostics, HydroCision, New Chemical Entities, sGC Pharma, Spirus Medical, Rachiotek, Pintex, Bessor Pharmaceuticals, and Vital Sensors.
Mr. Goldberg received an A.B. from Harvard College, a J.D. from Harvard Law School and an M.B.A. from Harvard Business School.